Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02879162
Title Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Canadian Cancer Trials Group
Age Groups: adult | child | senior
Covered Countries CAN

No variant requirements are available.